KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Receivables (2016 - 2025)

Neogenomics' Receivables history spans 16 years, with the latest figure at $159.2 million for Q4 2025.

  • For Q4 2025, Receivables rose 5.71% year-over-year to $159.2 million; the TTM value through Dec 2025 reached $159.2 million, up 5.71%, while the annual FY2025 figure was $159.2 million, 5.71% up from the prior year.
  • Receivables reached $159.2 million in Q4 2025 per NEO's latest filing, up from $155.3 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $159.2 million in Q4 2025 to a low of $104.9 million in Q1 2021.
  • Average Receivables over 5 years is $130.8 million, with a median of $128.7 million recorded in 2023.
  • The largest YoY upside for Receivables was 21.83% in 2021 against a maximum downside of 1.53% in 2021.
  • A 5-year view of Receivables shows it stood at $113.9 million in 2021, then increased by 6.8% to $121.6 million in 2022, then rose by 7.94% to $131.3 million in 2023, then rose by 14.76% to $150.6 million in 2024, then increased by 5.71% to $159.2 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Receivables are $159.2 million (Q4 2025), $155.3 million (Q3 2025), and $153.1 million (Q2 2025).